Poly[N‐(2‐hydroxypropyl)methacrylamide]‐Modified Magnetic γ‐F2O3 Nanoparticles Conjugated with Doxorubicin for Glioblastoma Treatment. (12th November 2019)
- Record Type:
- Journal Article
- Title:
- Poly[N‐(2‐hydroxypropyl)methacrylamide]‐Modified Magnetic γ‐F2O3 Nanoparticles Conjugated with Doxorubicin for Glioblastoma Treatment. (12th November 2019)
- Main Title:
- Poly[N‐(2‐hydroxypropyl)methacrylamide]‐Modified Magnetic γ‐F2O3 Nanoparticles Conjugated with Doxorubicin for Glioblastoma Treatment
- Authors:
- Plichta, Zdeněk
Horák, Daniel
Mareková, Dana
Turnovcová, Karolína
Kaiser, Radek
Jendelová, Pavla - Abstract:
- Abstract: With the aim to develop a new anticancer agent, we prepared poly[ N ‐(2‐hydroxypropyl)methacrylamide‐ co ‐methyl 2‐methacrylamidoacetate] [P(HP‐MMAA)], which was reacted with hydrazine to poly[ N ‐(2‐hydroxypropyl)methacrylamide‐ co ‐ N ‐(2‐hydrazinyl‐2‐oxoethyl)methacrylamide] [P(HP‐MAH)] to conjugate doxorubicin (Dox) via hydrazone bond. The resulting P(HP‐MAH)‐Dox conjugate was used as a coating of magnetic γ‐Fe2 O3 nanoparticles obtained by the coprecipitation method. In vitro toxicity of various concentrations of Dox, P(HP‐MAH)‐Dox, and γ‐Fe2 O3 @P(HP‐MAH)‐Dox nanoparticles was determined on somatic healthy cells (human bone marrow stromal cells hMSC), human glioblastoma line (GaMG), and primary human glioblastoma (GBM) cells isolated from GBM patients both at a short and prolonged exposition time (up to 7 days). Due to hydrolysis of the hydrazone bond in acid milieu of tumor cells and Dox release, the γ‐Fe2 O3 @P(HP‐MAH)‐Dox nanoparticles significantly decreased the GaMG and GBM cell growth compared to free Dox and P(HP‐MAH)‐Dox in low concentration (10 nM), whereas in hMSCs it remained without effect. γ‐F2 O3 @PHP nanoparticles alone did not affect the viability of any of the tested cells. Abstract : Doxorubicin (DOX) was conjugated via a degradable hydrazone bond to poly[ N ‐(2‐hydroxypropyl)methacrylamide] (PHP)‐coated maghemite nanoparticles, which significantly decreased cell growth of human glioblastoma cells. The particles can be thus suggested as aAbstract: With the aim to develop a new anticancer agent, we prepared poly[ N ‐(2‐hydroxypropyl)methacrylamide‐ co ‐methyl 2‐methacrylamidoacetate] [P(HP‐MMAA)], which was reacted with hydrazine to poly[ N ‐(2‐hydroxypropyl)methacrylamide‐ co ‐ N ‐(2‐hydrazinyl‐2‐oxoethyl)methacrylamide] [P(HP‐MAH)] to conjugate doxorubicin (Dox) via hydrazone bond. The resulting P(HP‐MAH)‐Dox conjugate was used as a coating of magnetic γ‐Fe2 O3 nanoparticles obtained by the coprecipitation method. In vitro toxicity of various concentrations of Dox, P(HP‐MAH)‐Dox, and γ‐Fe2 O3 @P(HP‐MAH)‐Dox nanoparticles was determined on somatic healthy cells (human bone marrow stromal cells hMSC), human glioblastoma line (GaMG), and primary human glioblastoma (GBM) cells isolated from GBM patients both at a short and prolonged exposition time (up to 7 days). Due to hydrolysis of the hydrazone bond in acid milieu of tumor cells and Dox release, the γ‐Fe2 O3 @P(HP‐MAH)‐Dox nanoparticles significantly decreased the GaMG and GBM cell growth compared to free Dox and P(HP‐MAH)‐Dox in low concentration (10 nM), whereas in hMSCs it remained without effect. γ‐F2 O3 @PHP nanoparticles alone did not affect the viability of any of the tested cells. Abstract : Doxorubicin (DOX) was conjugated via a degradable hydrazone bond to poly[ N ‐(2‐hydroxypropyl)methacrylamide] (PHP)‐coated maghemite nanoparticles, which significantly decreased cell growth of human glioblastoma cells. The particles can be thus suggested as a promising new anticancer agent. … (more)
- Is Part Of:
- ChemMedChem. Volume 15:Number 1(2020)
- Journal:
- ChemMedChem
- Issue:
- Volume 15:Number 1(2020)
- Issue Display:
- Volume 15, Issue 1 (2020)
- Year:
- 2020
- Volume:
- 15
- Issue:
- 1
- Issue Sort Value:
- 2020-0015-0001-0000
- Page Start:
- 96
- Page End:
- 104
- Publication Date:
- 2019-11-12
- Subjects:
- magnetic -- iron oxide -- N-(2-hydroxypropyl)methacrylamide -- doxorubicin -- cancer treatment
Pharmaceutical chemistry -- Periodicals
615.19005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1860-7187 ↗
http://www3.interscience.wiley.com/cgi-bin/jhome/110485305 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/cmdc.201900564 ↗
- Languages:
- English
- ISSNs:
- 1860-7179
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3172.254000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 12609.xml